Biofrontera AG

Biofrontera adds body cream to belixos® dermo-cosmetics series

Business news for the stock market

Leverkusen (pta025/08.02.2017/15:35) - Biofrontera AG expands its successful dermocosmetics series belixos®. Since February 1, a body cream with active plant extracts is available in a 150 ml tube. The special skin care is the sixth product of the belixos® line.

With its pleasant formulation, the cream is most suitable as intensive care for irritated and itchy skin. It contains the same active ingredients with anti-inflammatory Mahonia aquifolium as the popular belixos® cream. The body cream is aimed at users suffering from neurodermatitis, psoriasis, extremely dry skin or eczema, and who need a special daily basic care. It is offered through Amazon internationally and in German pharmacies at a price of 19.95 Euro.

In addition, two existing products of the belixos® series were optically revised and made more user-friendly in their dosage form. Both belixos® cream, which relieves irritation and inflammation of dry skin, as well as belixos® gel, which is the ideal care for redness and impurities, are now available in a hygienic pump dispenser. This renders the application of the products more comfortable and optimally protects the formulation.

Enquiries, please contact: Biofrontera AG
Thomas Schaffer, Chief Financial Officer
[phone]
[e-mail]

IR Germany: Brainwell Asset Solutions
Jürgen Benker
[phone]

IR UK: Seton Services
Toni Vallen
[phone]

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
[phone] / 7035
PR: Kirsten Thomas
[phone]

About Biofrontera

Biofrontera Group (FSE: B8F, ISIN DE0006046113) Biofrontera is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the US for the treatment of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel, a scalp tonic and acute roll-on, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor & public relations
phone: [phone]
e-mail: [e-mail]
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20170208025 ]